In the open-label, phase 1/2 study (NCT01970865), LOR was found to have intracranial and extracranial responses in patients with advanced NSCLC harboring ALK rearrangement, who experienced tumor progression during prior ALK TKI therapy, including alectinib.7 Here, ALK is linked to non-small cell lung carcinoma.